Theranostics: Innovative cancer diagnostics and cancer treatment
The theranostics center Theranosticum Vienna headed by Prof. Dr. Marcus Hacker, Prof. Dr. Werner Langsteger, and Prof. Dr. Markus Mitterhauser provides highly specialized nuclear medicine diagnostics and personalized outpatient treatments for various types of cancer at the Institute for Nuclear Medicine and Isotope Diagnostics at Döbling Outpatient Center. These innovative treatments allow tumor cells to be specifically damaged while at the same time sparing healthy tissue.
The treatment is provided on an outpatient basis in the safe environment of Döbling Private Hospital and Döbling Outpatient Center, with no need for hospital stays lasting several days.
It treats advanced cancers where a tumor continues to grow despite all conventional treatments being used. The method is primarily used for:
- Metastatic prostate cancer
- Metastatic neuroendocrine tumors
- Advanced stages of various tumors of the mammary gland, lung, pancreas, or colon
The treatment can extend a patient’s life and also significantly improve their quality of life due to the good tolerance levels for the treatment. Numerous studies show that the treatment can achieve good results in cases of prostate cancer in particular.
The following examination results must be available and the corresponding prerequisites must be met for any treatment:
- PSMA PET/CT imaging – showing the characteristics of the tumor tissue. The images and results must be no more than 6 weeks old.
- Multidisciplinary tumor board decision and/or urological referral
- Current laboratory results (blood count and PSA tumor markers)
- Adequate kidney and bone marrow function
2. Outpatient treatment
The treatment is administered intravenously via venous access in the arm during outpatient treatment at Theranosticum Vienna. The entire procedure lasts no longer than 1 hour. The radiation emitted by the patient is measured before discharge in accordance with the statutory radiation protection requirements.
Regular laboratory tests (blood count incl. kidney and liver parameters) are essential in monitoring the patient’s health status. These should generally be performed at intervals of between 2 and 4 weeks.
A new PSMA PET/CT result is required 4 weeks following the 3rd cycle of treatment in order to review the success of the treatment and to enable the further cycles to be planned.